List of Excipients in Branded Drug LEADER IBUPROFEN

« Back to Dashboard

Generic Drugs Containing LEADER IBUPROFEN

Company	Ingredient	NDC	Excipient
RPK Pharmaceuticals Inc	ibuprofen	53002-5711	CELLULOSE, MICROCRYSTALLINE
RPK Pharmaceuticals Inc	ibuprofen	53002-5711	CROSCARMELLOSE SODIUM
RPK Pharmaceuticals Inc	ibuprofen	53002-5711	FERRIC OXIDE RED
RPK Pharmaceuticals Inc	ibuprofen	53002-5711	FERRIC OXIDE YELLOW
RPK Pharmaceuticals Inc	ibuprofen	53002-5711	HYPROMELLOSE

What are the Most Frequently-Used Excipients in LEADER IBUPROFEN?

# Of NDCs	Excipient
2	ACESULFAME POTASSIUM
2	AMMONIUM GLYCYRRHIZATE
3	ANHYDROUS CITRIC ACID
2	ASPARTAME
2	CARNAUBA WAX

Leader Ibuprofen Excipient Strategy and Commercial Opportunities

Last updated: October 28, 2026

Leader Ibuprofen is a private-label, over-the-counter ibuprofen product competing primarily on price, availability, dosage-form breadth, and retailer distribution. Its active ingredient is mature and broadly commoditized, so commercial differentiation depends on manufacturing cost, excipient performance, packaging, tolerability, and product extensions rather than on drug-substance exclusivity.

The strongest opportunities are immediate-release tablets, softgels, pediatric suspensions, easy-swallow formats, and differentiated packaging. The main technical constraints are ibuprofen’s low aqueous solubility, taste, tablet disintegration, content uniformity, gastrointestinal tolerability, and supply-chain cost.

What is Leader Ibuprofen?

Leader is a private-label consumer-health brand associated with Cardinal Health and distributed through pharmacies, hospitals, retailers, and e-commerce channels. Leader Ibuprofen products generally contain ibuprofen as the active ingredient, with common OTC strengths including 200 mg tablets or capsules. Product availability and labeling can vary by retailer, dosage form, package size, and contract manufacturer.

Under U.S. OTC labeling, ibuprofen is marketed as a nonsteroidal anti-inflammatory drug for temporary relief of minor aches and pains and reduction of fever. The standard adult OTC dose is 200 mg, with a maximum daily dose of 1,200 mg unless directed by a physician.[1]

Core product categories

Product type	Typical strength	Primary use	Commercial role
Immediate-release tablet	200 mg	General pain and fever	Lowest-cost volume product
Film-coated caplet	200 mg	Easier swallowing and handling	Premium private-label format
Softgel capsule	200 mg	Perceived fast action	Higher-margin extension
Children’s oral suspension	100 mg/5 mL	Pediatric pain and fever	Family-health segment
Chewable tablet	50 mg or 100 mg, market-dependent	Pediatric use	Taste and compliance segment
Combination product	Varies	Cold, flu, or menstrual symptoms	Higher regulatory and labeling complexity

What excipients are used in Leader Ibuprofen?

The exact inactive ingredients depend on the Leader SKU and contract manufacturer. Typical immediate-release ibuprofen tablets use excipients in five functional groups: fillers, binders, disintegrants, lubricants, and coating materials.

Typical excipient architecture

Excipient function	Common materials	Technical purpose
Diluent	Microcrystalline cellulose, lactose, starch, calcium phosphate	Adds bulk and improves compression
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Croscarmellose sodium, sodium starch glycolate, crospovidone	Promotes rapid breakup after ingestion
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate, stearic acid, sodium stearyl fumarate	Reduces sticking and ejection force
Film coating	Hypromellose, polyethylene glycol, talc, titanium dioxide, colorants	Improves appearance, swallowability, and handling
Suspension vehicle	Water, glycerin, sorbitol, cellulose derivatives	Supports pediatric liquid delivery
Suspending agent	Xanthan gum, sodium carboxymethylcellulose, microcrystalline cellulose blends	Maintains dose uniformity
Sweetener and flavor	Sucralose, saccharin sodium, sucrose, fruit flavors	Masks ibuprofen bitterness

Ibuprofen has poor water solubility. This characteristic can slow dissolution and create sensitivity to particle size, wetting, granulation, compression force, and lubricant concentration. The formulation objective is usually rapid, reproducible dissolution without excessive manufacturing cost.

Why excipient selection matters

Poorly balanced formulations can produce:

• Slow disintegration from excessive compression or hydrophobic lubrication.
• Dissolution variability caused by coarse ibuprofen particles.
• Tablet capping or lamination.
• Poor content uniformity in low-dose pediatric products.
• Bitter taste and low adherence in liquid or chewable products.
• Sedimentation or dose nonuniformity in suspensions.
• Sticking during compression because of inadequate lubrication or unsuitable tooling.

FDA’s OTC monograph framework does not eliminate the need for quality controls. Finished products must meet applicable identity, strength, quality, purity, packaging, and labeling requirements under current good manufacturing practice rules.[1,2]

How should an excipient strategy be designed for Leader Ibuprofen?

The best strategy is a platform approach that uses a limited number of excipient systems across multiple private-label formats.

1. Optimize the 200 mg immediate-release tablet

The 200 mg tablet is the cost anchor. A formulation should prioritize:

• High tablet tensile strength at moderate compression force.
• Disintegration within the applicable product specification.
• Rapid dissolution across relevant media.
• Low lubricant sensitivity.
• Compatibility with direct compression or efficient dry granulation.
• Minimal coating weight.
• Reliable performance across multiple ibuprofen suppliers.

Microcrystalline cellulose, a superdisintegrant, colloidal silicon dioxide, and magnesium stearate can support a conventional direct-compression platform. Dry granulation may improve flow and content uniformity when the selected ibuprofen grade has poor flow or broad particle-size distribution.

2. Use film coating to support premium positioning

Film coating can make a basic generic tablet easier to swallow and more visually distinct. A thin hypromellose-based coating can reduce chalkiness, mask odor, improve abrasion resistance, and support color coding by strength.

The coating should not materially delay dissolution. Excessive coating weight or poorly selected polymer systems can undermine the principal product claim of rapid relief.

3. Develop a softgel or liquid-filled capsule

Softgels create a higher-priced alternative to standard tablets. Ibuprofen may be formulated as a solubilized or suspended liquid fill using suitable polyethylene glycol, surfactant, and viscosity-control systems. The opportunity is commercial rather than patent-driven.

Key development issues include:

• Chemical stability of ibuprofen in the fill.
• Gel-shell compatibility.
• Migration of fill components into the gelatin shell.
• Oxygen and moisture protection.
• Dissolution after shell rupture.
• Manufacturing yield and capsule leakage.

Softgels can command stronger shelf placement and online search visibility, but they carry higher packaging, equipment, and quality-control costs than tablets.

4. Improve pediatric liquid performance

Children’s ibuprofen suspensions have greater excipient differentiation potential than standard adult tablets. The leading opportunities are:

• Lower-sugar or sugar-free formulations.
• Better taste masking.
• Reduced settling and easier redispersion.
• Accurate dosing with oral syringes.
• Preservative systems compatible with the pH and packaging.
• Reduced staining and less viscous mouthfeel.

A robust suspension should maintain uniform ibuprofen concentration throughout the labeled shelf life and after routine consumer handling. Packaging with a calibrated oral syringe can create a practical advantage over products supplied only with a cup.

5. Address allergen and consumer-label preferences

Excipients can support claims such as dye-free, sugar-free, alcohol-free, gluten-free, or lactose-free, subject to substantiation and labeling controls. These claims can improve retailer acceptance and support premium pricing, but they require disciplined supplier qualification and change control.

What commercial opportunities exist for Leader Ibuprofen?

Value-tier private label

The largest opportunity remains low-cost 200 mg ibuprofen. Cost reductions can come from:

• Multi-source active pharmaceutical ingredient procurement.
• Standardized excipient platforms.
• High-speed compression.
• Reduced coating weight.
• Larger production campaigns.
• Common blister and bottle components across SKUs.
• Contract manufacturing near major distribution centers.

For a mature OTC product, small reductions in tablet cost can materially affect gross margin when annual unit volumes are high.

Premium private label

Leader can differentiate through:

• Film-coated caplets.
• Easy-open bottles.
• Single-dose blister packaging.
• Travel-size formats.
• Softgels.
• Fast-dissolving or easy-swallow tablets.
• Dye-free and sugar-free pediatric products.

These extensions compete with branded products such as Advil while retaining the private-label price advantage.

Institutional and healthcare channels

Leader’s association with pharmacy and healthcare distribution creates opportunities in:

• Hospital outpatient pharmacies.
• Long-term-care facilities.
• Employee health clinics.
• Occupational-health programs.
• Government and institutional procurement.
• Multi-dose pharmacy packaging.

Institutional buyers generally prioritize reliable supply, unit cost, packaging efficiency, and documentation over consumer-facing brand differentiation.

E-commerce and multipack formats

Online channels support larger bottles and multipacks. A 500-count or 1,000-count package can reduce per-tablet packaging cost, but it also raises inventory, expiration, and child-resistant closure considerations.

Search-driven retail opportunities include “ibuprofen 200 mg,” “pain reliever,” “fever reducer,” “dye free ibuprofen,” “ibuprofen softgels,” and “children’s ibuprofen.” Packaging must remain compliant with OTC labeling and avoid unsupported superiority claims.

What patents protect Leader Ibuprofen?

No material product-specific patent estate is expected to protect conventional Leader Ibuprofen 200 mg tablets. Ibuprofen was discovered and commercialized decades ago, and basic composition, conventional tablet, and ordinary use claims are generally expired or unavailable as barriers to generic entry.

Commercial protection is based on brand ownership, retailer relationships, manufacturing contracts, trade dress, quality systems, and distribution scale. Excipients may be covered by supplier patents or proprietary formulation know-how, but ordinary use of standard excipients in a conventional ibuprofen tablet generally does not create a durable blocking right.

Patent and exclusivity overview

Protection category	Expected status for conventional Leader Ibuprofen
Ibuprofen active ingredient	No meaningful basic composition exclusivity
200 mg immediate-release tablet	Generic and commercially mature
Standard excipient combination	Usually non-proprietary or broadly available
Softgel delivery system	May involve third-party know-how or formulation patents
Pediatric taste-masked suspension	Possible formulation and trade-secret protection
Brand name “Leader”	Trademark and private-label branding protection
Packaging design	Trade dress, design rights, and retailer-specific control
Manufacturing process	Confidential know-how and supplier controls

When does Leader Ibuprofen lose exclusivity?

Leader Ibuprofen has no conventional prescription-drug exclusivity timeline comparable to a new FDA-approved drug. A standard OTC ibuprofen product can be marketed by multiple manufacturers under the applicable FDA OTC framework if it meets monograph and manufacturing requirements.

The product’s commercial protection therefore does not depend on a single expiration date. Competition can enter through:

• Other private-label retailers.
• Authorized generics.
• National OTC brands.
• Contract-manufactured store brands.
• Online direct-to-consumer sellers.
• Combination analgesic products.

What is the FDA regulatory status of Leader Ibuprofen?

Ibuprofen is an established OTC active ingredient regulated under FDA’s OTC monograph system for internal analgesic, antipyretic, and antirheumatic products. The relevant regulatory framework includes the FDA’s OTC monograph provisions and 21 C.F.R. Part 343.[1]

Regulatory considerations

A conventional Leader product must address:

• Active ingredient identity and strength.
• Required Drug Facts labeling.
• Dose and age restrictions.
• Warnings concerning stomach bleeding, allergic reactions, cardiovascular risk, and pregnancy.
• Child-resistant packaging where required.
• Stability and expiration dating.
• Finished-product testing.
• Current good manufacturing practice.
• Adverse-event reporting and complaint handling.

The product is not dependent on an NDA-based market exclusivity period when marketed within the applicable OTC framework.

Are there Paragraph IV challenges or biosimilar risks?

Paragraph IV litigation and biosimilar competition are not central risks for a conventional Leader Ibuprofen product.

Paragraph IV certifications apply primarily to abbreviated new drug applications referencing listed drug patents. A standard OTC ibuprofen product marketed under the monograph system typically does not present the same Orange Book patent-certification profile as a patented prescription drug.

Biosimilar risk is not relevant because ibuprofen is a small-molecule chemical active ingredient, not a biologic. Competitive risk comes from other generic and private-label manufacturers.

What formulation patents and manufacturing barriers matter?

The most relevant barriers are formulation execution and supply reliability rather than broad patent exclusion.

Formulation barriers

Potentially defensible technical areas include:

• Rapid-dissolution ibuprofen particles.
• Taste-masked pediatric suspensions.
• Improved softgel fill systems.
• Low-dose chewable formulations.
• Abuse-resistant or child-resistant packaging.
• Stable preservative systems.
• Modified-release delivery, although this adds regulatory complexity.

These areas may support patents if the formulation has a novel composition and measurable technical benefit. Routine combinations of standard excipients are less likely to provide strong patent protection.

Manufacturing barriers

Key barriers include:

• Consistent ibuprofen particle-size control.
• Control of polymorphic form and physical properties.
• High-throughput compression without sticking.
• Reproducible dissolution after scale-up.
• Suspension uniformity over shelf life.
• Reliable blister and bottle supply.
• Qualification of alternate API and excipient suppliers.
• Compliance with OTC monograph and cGMP requirements.

How strong is the Leader Ibuprofen commercial position?

The commercial position is strong in value retail and distribution but weak in legal exclusivity. Leader can compete effectively where it has:

1. Retail or institutional shelf access.
2. Low landed cost.
3. Reliable supply.
4. Broad package-size coverage.
5. A differentiated pediatric or softgel product.
6. Consistent quality and complaint performance.

The main risks are price compression, retailer delisting, manufacturing recalls, API shortages, packaging inflation, and substitution by competing store brands.

How does Leader Ibuprofen compare with branded Advil?

Factor	Leader Ibuprofen	Advil
Active ingredient	Ibuprofen	Ibuprofen
Typical consumer positioning	Value and private label	National brand
Price	Usually lower	Usually higher
Patent dependence	Low	Low for basic ibuprofen products
Main advantage	Distribution and price	Brand recognition and marketing
Excipient differentiation	SKU-dependent	Product-line and dosage-form extensions
Retail leverage	Strong where retailer-owned	Broad national presence
Generic substitution risk	High	High but offset by brand loyalty

Leader’s best path is not to replicate branded marketing expenditure. It is to reduce manufacturing cost, improve format selection, and occupy underserved price and convenience tiers.

What generic launch scenarios exist?

Low-risk scenario

A manufacturer enters with a conventional 200 mg tablet using standard excipients and competes on price. This scenario produces rapid commoditization and limited margin.

Moderate-opportunity scenario

A manufacturer launches film-coated caplets, softgels, or large-count value packs. Differentiation improves, but competing formats are easy to copy.

Higher-value scenario

A manufacturer launches a well-differentiated pediatric suspension or chewable product with strong taste masking, accurate dosing, and superior stability. This creates greater consumer value and retailer differentiation, although development and compliance costs are higher.

Key Takeaways

• Leader Ibuprofen is primarily a private-label OTC and distribution opportunity, not a patent-exclusivity opportunity.
• The 200 mg immediate-release tablet is the cost and volume anchor.
• Excipients should be selected to control dissolution, tablet robustness, flow, taste, and manufacturing yield.
• Pediatric suspensions, softgels, film-coated caplets, and convenient packaging offer the strongest commercial extensions.
• Conventional ibuprofen products face no meaningful biosimilar risk and limited Paragraph IV exposure.
• Formulation know-how, supplier qualification, packaging, and retail access are more important than basic patent rights.
• The strongest commercial strategy is a multi-SKU platform using common excipients and packaging components across adult and pediatric products.

FAQs About Leader Ibuprofen Excipient Strategy

Does Leader Ibuprofen contain lactose?

The answer depends on the specific Leader dosage form and manufacturer. Inactive ingredients can vary by SKU, tablet, capsule, suspension, and package configuration.

Can ibuprofen be formulated without magnesium stearate?

Yes. Alternative lubricants include sodium stearyl fumarate, stearic acid, and other technically suitable systems. The replacement must be evaluated for ejection force, sticking, dissolution, and stability.

Is a fast-release ibuprofen product patentable?

Potentially, but a patent requires a novel and non-obvious formulation or process with supporting technical evidence. A conventional superdisintegrant substitution is unlikely to create strong exclusivity by itself.

What is the best premium format for private-label ibuprofen?

Softgels and film-coated caplets generally offer the clearest consumer-facing differentiation. Pediatric liquids can offer greater technical differentiation but require more extensive stability and taste development.

Can Leader Ibuprofen be sold through hospitals and institutional pharmacies?

Yes. Institutional sales depend on applicable OTC compliance, procurement qualifications, supply reliability, packaging requirements, pricing, and distributor access.

References

1. U.S. Food and Drug Administration. (2024). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. Electronic Code of Federal Regulations.

2. U.S. Food and Drug Administration. (2024). Current good manufacturing practice, quality system regulation, and related requirements for drug products. FDA.

3. U.S. Food and Drug Administration. (2024). Drug Facts labeling requirements for over-the-counter drug products. FDA.

4. National Library of Medicine. (2024). DailyMed: Ibuprofen drug labels. U.S. National Library of Medicine.

5. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.